These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1005 related items for PubMed ID: 9087972
1. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Rioux L, Frohna PA, Joyce JN, Schneider JS. Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972 [Abstract] [Full Text] [Related]
2. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T. Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337 [Abstract] [Full Text] [Related]
3. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115 [Abstract] [Full Text] [Related]
6. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. Ouattara B, Gasparini F, Morissette M, Grégoire L, Samadi P, Gomez-Mancilla B, Di Paolo T. J Neurochem; 2010 May 01; 113(3):715-24. PubMed ID: 20132464 [Abstract] [Full Text] [Related]
9. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T. Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):446-54. PubMed ID: 20026151 [Abstract] [Full Text] [Related]
10. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bédard PJ, Di Paolo T. Brain Res Mol Brain Res; 1997 Oct 03; 49(1-2):55-62. PubMed ID: 9387863 [Abstract] [Full Text] [Related]
11. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Mov Disord; 2006 Jan 03; 21(1):9-17. PubMed ID: 16127720 [Abstract] [Full Text] [Related]
16. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Graham WC, Sambrook MA, Crossman AR. Brain Res; 1993 Feb 05; 602(2):290-303. PubMed ID: 8095431 [Abstract] [Full Text] [Related]
19. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Pope-Coleman A, Tinker JP, Schneider JS. Synapse; 2000 May 05; 36(2):120-8. PubMed ID: 10767059 [Abstract] [Full Text] [Related]
20. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Przedborski S, Jackson-Lewis V, Popilskis S, Kostic V, Levivier M, Fahn S, Cadet JL. Neurochirurgie; 1991 May 05; 37(6):377-82. PubMed ID: 1780015 [Abstract] [Full Text] [Related] Page: [Next] [New Search]